ArticleEuropean radiology2026
Prognostic value of the number of imaging-detected lymph node metastases diagnosed by combined FDG-PET/CT and Node-RADS in HPV-associated oropharyngeal carcinoma.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesTo evaluate the prognostic value of the number of imaging-detected lymph node metastases (iLNM) in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC), addressing the discrepancy between clinical and pathological N staging. MATERIALS AND
methodsWe retrospectively enrolled consecutive patients with HPV-associated OPSCC between January 2014 and December 2024. Lymph node metastases were defined as nodes with SUVmax ≥ 3.5 or Node-RADS score ≥ 3. Two readers evaluated iLNM number, nodal SUVmax, and imaging-detected extranodal extension (iENE). Kaplan-Meier analysis was used to estimate 5-year overall survival (OS) and event-free survival (EFS; recurrence or disease-related death), stratified by clinical stage (cStage, UICC 9th edition), nodal SUVmax, iLNM number, and iENE. Firth-penalized Cox proportional hazards models were used for univariable and multivariable analyses.
resultsSixty-eight patients (median age, 66; male:female = 55:13) were included. The 5-year OS and EFS were 80% and 77%, respectively. The primary Firth-penalized Cox model showed that iLNM ≥ 5 was associated with poorer OS (hazard ratio (HR), 11.4; 95% confidence interval [CI], 3.1-44.5) and EFS (HR, 6.5; 95% CI, 2.0-20.1). A sensitivity analysis additionally adjusting for cStage (III) yielded similar effect estimates for both OS (HR, 10.7; 95% CI, 2.6-46.0) and EFS (HR, 7.7; 95% CI, 2.0-27.2), supporting the consistency of the observed association after clinical adjustment.
conclusionThe number of iLNM may serve as a prognostic imaging biomarker for risk stratification in HPV-associated OPSCC, aligning with pathological nodal staging and improving clinical prognostic assessment. KEY POINTS: Question Discrepancies between clinical and pathological nodal staging in the 9th UICC TNM classification for HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) remain an unsolved clinical problem. Findings The number of imaging-detected lymph node metastases (iLNM), defined as lymph nodes with SUVmax ≥ 3.5 or Node-RADS score ≥ 3, was identified as an independent prognostic factor in HPV-associated OPSCC. Clinical relevance Incorporating the number of iLNM into clinical nodal staging, using an approach similar to pathological nodal staging, may improve risk stratification and enable more accurate prognostic assessment in HPV-associated OPSCC.
Indexed as
Identifiers
42823561What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.